Profile data is unavailable for this security.
About the company
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
- Revenue in CNY (TTM)730.70m
- Net income in CNY-18.88m
- Incorporated1990
- Employees1.43k
- LocationShanghai Fudan Forward S&T Co LtdNo. 525, Guoquan RoadSHANGHAI 200433ChinaCHN
- Phone+86 2 163872288
- Fax+86 2 163869700
- Websitehttp://www.forwardgroup.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ningbo Menovo Pharmaceutical Co Ltd | 1.15bn | 179.28m | 2.97bn | 2.30k | 18.33 | 1.38 | -- | 2.57 | 0.76 | 0.76 | 4.84 | 10.09 | 0.2519 | 1.13 | 3.90 | 502,754.30 | 4.20 | 6.36 | 6.45 | 10.23 | 32.12 | 36.35 | 16.69 | 16.05 | 0.9153 | -- | 0.4083 | 12.64 | 15.80 | 19.20 | 137.67 | 49.95 | 45.98 | 8.97 |
Henan Taloph Pharmaceutical Stock Co Ltd | 2.11bn | -32.19m | 2.98bn | 2.66k | -- | 2.00 | -- | 1.42 | -0.0568 | -0.0568 | 3.74 | 2.59 | 0.6122 | 3.84 | 2.39 | 792,445.10 | -1.07 | -0.7076 | -2.13 | -1.25 | 25.06 | 29.08 | -1.76 | -1.53 | 0.8044 | 0.2333 | 0.3233 | -- | 22.20 | 10.91 | -1,303.26 | -- | 8.48 | -- |
Shanghai ZJ Bio-Tech Co Ltd | 648.65m | 166.57m | 3.02bn | 435.00 | 17.96 | 0.7468 | -- | 4.66 | 0.8645 | 0.8645 | 3.34 | 20.80 | 0.1458 | 0.6238 | 2.67 | 1,491,159.00 | 3.74 | 25.68 | 4.11 | 29.10 | 56.90 | 63.39 | 25.68 | 37.27 | 13.78 | -- | 0.0015 | 31.50 | 15.23 | 64.57 | 0.2305 | 71.31 | 21.08 | -- |
Shanghai Fudan Forward S&T Co Ltd | 730.70m | -18.88m | 3.07bn | 1.43k | -- | 3.53 | -- | 4.20 | -0.0278 | -0.0278 | 1.08 | 1.27 | 0.3943 | 0.6766 | 8.37 | 512,413.10 | -0.8747 | -0.4088 | -1.49 | -0.7204 | 39.19 | 45.22 | -2.22 | -0.8611 | 0.584 | 0.3701 | 0.3741 | -- | -24.23 | 1.41 | 96.58 | -- | -3.22 | -- |
Data as of Mar 28 2024. Currency figures normalised to Shanghai Fudan Forward S&T Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 29 Feb 2024 | 677.45k | 0.10% |
Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 452.63k | 0.07% |
China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 38.00k | 0.01% |
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
GF Fund Management Co., Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.